KELER TIBOR
Known title: EXECUTIVE VP & CSOCIK: 0001429931
Associated companies
Transaction History
| CLDX | ▲ Buy | Option Exercise | 16,860 | $47K | 12/7/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 16,860 | $623K | 12/7/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 16,860 | $47K | 12/7/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 16,860 | $623K | 12/7/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.